These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Therapeutic approaches to the treatment of hairy cell leukemia. Portlock CS Semin Oncol; 1986 Dec; 13(4 Suppl 5):55-9. PubMed ID: 3541219 [TBL] [Abstract][Full Text] [Related]
23. Chemotherapy, cytokines, and biochemotherapy for melanoma. Eton O Cancer Chemother Biol Response Modif; 2005; 22():739-48. PubMed ID: 16110637 [No Abstract] [Full Text] [Related]
24. Role of interferon-alfa in NHL: still controversial? Haase-Statz S; Smalley RV Oncology (Williston Park); 1999 Aug; 13(8):1147-59; discussion 1159-60, 1163. PubMed ID: 10499247 [TBL] [Abstract][Full Text] [Related]
25. Treatment of chemotherapy-refractory metastatic urothelial tumors. Logothetis C Urol Clin North Am; 1992 Nov; 19(4):775-7. PubMed ID: 1441031 [TBL] [Abstract][Full Text] [Related]
26. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356 [TBL] [Abstract][Full Text] [Related]
27. [Clinical observation of interferon alpha-2b intralesional injection in treatment of childhood refractory solid tumor]. Sun LR; Pang XY; Lu Y; Li XR; Song AQ; Dong Q Zhonghua Er Ke Za Zhi; 2003 May; 41(5):374-5. PubMed ID: 14751066 [No Abstract] [Full Text] [Related]
28. Maintenance treatment of primary plasma cell leukemia with interferon alpha. Cernelc P; Mlakar U Transplant Proc; 2002 Nov; 34(7):2929-30. PubMed ID: 12431661 [No Abstract] [Full Text] [Related]
29. [Chronic myeloid leukemia. What's in the future therapy in Black Africa?]. Dokekias AE; Malanda F; Mbalawa ChG Tunis Med; 2003 Mar; 81(3):172-9. PubMed ID: 12793067 [No Abstract] [Full Text] [Related]
31. [Combination chemotherapy of MCNU and interferon alfa-2a (genetical recombination) for advanced multiple myeloma]. Hino N; Matsuura W; Kawakami K; Ono T; Matsumoto T; Tominaga T Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):693-6. PubMed ID: 2321988 [No Abstract] [Full Text] [Related]
32. Recent advances in medical oncology--1995-1996. Sikov WM Med Health R I; 1996 Mar; 79(3):92-9. PubMed ID: 8901289 [No Abstract] [Full Text] [Related]
33. Combination of chemotherapy and interferon alfa-2b in the treatment of chronic myelogenous leukemia. Freund M; Hild F; Grote-Metke A; Nowak R; Otremba B; Wörmann B; Koch O; Dohmen M; Kleine HD; Link H Semin Hematol; 1993 Jul; 30(3 Suppl 3):11-3. PubMed ID: 8235696 [No Abstract] [Full Text] [Related]
34. [Treatment of low malignancy non-Hodgkin lymphomas with recombinant interferon. Current status]. Neubauer A; Herrmann R Med Klin (Munich); 1989 Jul; 84(7):355-8. PubMed ID: 2677632 [No Abstract] [Full Text] [Related]
36. [Recombinant alpha-interferon (reaferon) in the treatment of patients with chronic myeloleukemia]. Khoroshko ND; Savchenko VG; Kholopova EI; Kotel'nikov VM; Zakharova AV; Semenova EA; Marchenko VI Ter Arkh; 1990; 62(7):41-7. PubMed ID: 2251664 [TBL] [Abstract][Full Text] [Related]
37. The role of adjuvant interferon in high risk melanoma patients. Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951 [No Abstract] [Full Text] [Related]
38. Recombinant alpha-2a interferon in the treatment of refractory anemia with excess of blasts. Rossi G; Pagetto A; Boverio R; Montanaro G Haematologica; 1990; 75(1):97-8. PubMed ID: 2338298 [No Abstract] [Full Text] [Related]